Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled phase 2 study of orvepitant for chronic refractory cough
2016-004979-49Phase 2Completed
- Sponsor
- NeRRe Therapeutics
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orvepitant in refractory chronic cough (RCC) and chronic cough (4 arms), sponsored by NeRRe Therapeutics. Primary endpoint: Change from baseline to Week 12 in awake objective cough frequency. Started Apr 2017; status: completed.
02
Drugs
orvepitant
03
Conditions
refractory chronic cough (RCC)chronic cough
Beyond the preview
Go deeper on 2016-004979-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004979-49.